GLP-1 Medication Before IVF and Fertility Treatment: What to Know

Why weight comes up before IVF in the first place

Obesity is associated with lower IVF success rates across multiple measures — egg yield, embryo quality, and live birth rate have all been linked to higher BMI in systematic reviews of assisted reproduction outcomes¹⁶. That's the reason "lose weight first" is common advice before starting a cycle, and it's grounded in real data — a narrative review on preconception weight reduction in women and men with obesity and infertility lays out the case in detail². But the same body of evidence carries an honest complication: a randomised nested-cohort study found a structured lifestyle intervention before IVF did *not* improve embryo utilization rate or cumulative live birth rate compared with going straight to treatment⁵. Weight loss is associated with better outcomes in observational data; a specific intervention to produce that weight loss didn't reproduce the benefit in this one trial. That gap matters, and it's worth knowing before assuming a GLP-1 will function as a reliable fertility booster on its own.

What the newest reproductive-health evidence on GLP-1s specifically shows

A comprehensive 2026 systematic review integrating IVF data, ovarian physiology, and molecular mechanisms found a genuinely mixed picture. In clinical studies, GLP-1 receptor agonists improved menstrual regularity and lowered free testosterone in women with PCOS, and — notably — liraglutide combined with metformin significantly improved IVF pregnancy rates in one line of research, while exenatide was linked to increased natural conception rates in another³. At the same time, animal and cellular studies in the same review found a *context-dependent* effect on the ovary — GLP-1 receptor activation supported follicular growth in some models and triggered oxidative stress and granulosa cell death in others, depending on dose and timing³. A separate 2025 review focused on non-PCOS reproductive health reached a similarly nuanced conclusion: real potential benefit, alongside real unknowns about dosing and duration in a fertility-treatment context specifically⁴.

The timing question that matters most: washout before transfer

Perhaps the most clinically useful — and least publicized — finding is about *timing* relative to a cycle, not just whether to use a GLP-1 at all. A 2025 study on GLP-1 receptor agonists and endometrial receptivity found the medication's effects extend to the lining that has to support implantation, not just to ovarian function⁷ — which is a direct argument for coordinating a washout period with a reproductive endocrinologist ahead of egg retrieval or, especially, embryo transfer, rather than continuing treatment right up to a cycle by default. This is the same logic behind the "stop before trying to conceive" guidance we cover in our GLP-1 and birth control guide, applied here to a scheduled, medically-monitored cycle where the timing can actually be planned in advance with your RE.

What this means in practice

If you're heading into IVF or another fertility treatment and currently on a GLP-1, or considering starting one beforehand: this needs to be a three-way conversation between your reproductive endocrinologist, your GLP-1 prescriber, and you, with the RE setting the washout timeline relative to your specific protocol — not a decision made by either clinician in isolation. If PCOS is part of your fertility picture, the menstrual-regularity and testosterone benefits found in the research above are a genuine reason a GLP-1 might help beyond weight alone, which our PCOS guide covers from the metabolic side. And go in with realistic expectations: weight loss is associated with better IVF outcomes in the population-level data, but a specific weight-loss intervention did not reliably translate to better live birth rates in at least one controlled trial — so a GLP-1 is worth discussing as one part of a fertility plan, not treated as a guaranteed fix on its own. This guide is educational only and not medical advice.